Inflammatory fibroblasts make rectal cancer resistant to radiation therapy

Rana Mhaidly; Fatima Mechta-Grigoriou

doi:10.1016/j.ccell.2022.01.005

Inflammatory fibroblasts make rectal cancer resistant to radiation therapy

Cancer Cell. 2022 Feb 14;40(2):122-124. doi: 10.1016/j.ccell.2022.01.005. Epub 2022 Feb 3.

Authors

Rana Mhaidly¹, Fatima Mechta-Grigoriou²

Affiliations

¹ Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, 26, Rue d'Ulm, 75248 Paris, France; Inserm, U830, 26, Rue d'Ulm, 75005 Paris, France.
² Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, 26, Rue d'Ulm, 75248 Paris, France; Inserm, U830, 26, Rue d'Ulm, 75005 Paris, France. Electronic address: fatima.mechta-grigoriou@curie.fr.

PMID: 35120597
DOI: 10.1016/j.ccell.2022.01.005

Abstract

Colorectal cancer (CRC) is one of the most prevalent cancers worldwide. Still, the molecular mechanisms that drive CRC therapy resistance are incompletely understood. In this issue of Cancer Cell, Nicolas et al. combine several approaches to unravel a critical role for inflammatory cancer-associated fibroblasts (iCAFs) and interleukin 1α (IL1α) signaling in radiotherapy resistance.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cancer-Associated Fibroblasts*
Fibroblasts
Humans
Rectal Neoplasms* / radiotherapy